CSL's (ASX:CSL) Switzerland-based pharmaceutical unit, CSL Vifor, and US biopharmaceutical firm Travere Therapeutics said the European Commission has granted standard marketing authorization for Filspari, a treatment for primary IgA nephropathy (IgAN), a rare and progressive kidney disease, according to a Tuesday statement by the company.
The decision converts a previous conditional marketing authorization and extends to all European Union member states, as well as Iceland, Liechtenstein, and Norway, the company said.
Filspari was developed by Travere Therapeutics and exclusively licensed to CSL Vifor for commercialization in Europe, Australia, and New Zealand.
CSL's shares rose 1% in recent Wednesday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。